Back to Search
Start Over
Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment
- Source :
- Cancers, Cancers; Volume 11; Issue 8; Pages: 1171, Cancers, Vol 11, Iss 8, p 1171 (2019)
- Publication Year :
- 2019
- Publisher :
- MDPI, 2019.
-
Abstract
- The aim of this study was to assess the prognostic and predictive value of an untargeted assessment of tumor fractions in the plasma of metastatic breast cancer patients and to compare circulating tumor DNA (ctDNA) with circulating tumor cells (CTC) and conventional tumor markers. In metastatic breast cancer patients (n = 29), tumor fractions in plasma were assessed using the untargeted mFAST-SeqS method from 127 serial blood samples. Resulting z-scores for the ctDNA were compared to tumor fractions established with the recently published ichorCNA algorithm and associated with the clinical outcome. We observed a close correlation between mFAST-SeqS z-scores and ichorCNA ctDNA quantifications. Patients with mFAST-SeqS z-scores above three (34.5%) showed significantly worse overall survival (p = 0.014) and progression-free survival (p = 0.018) compared to patients with lower values. Elevated z-score values were clearly associated with radiologically proven progression. The baseline CTC count, carcinoembryonic antigen (CEA), and cancer antigen (CA)15-5 had no prognostic impact on the outcome of patients in the analyzed cohort. This proof of principle study demonstrates the prognostic impact of ctDNA levels detected with mFAST-SeqS as a very fast and cost-effective means to assess the ctDNA fraction without prior knowledge of the genetic landscape of the tumor. Furthermore, mFAST-SeqS-based ctDNA levels provided an early means of measuring treatment response.
- Subjects :
- 0301 basic medicine
Oncology
mFAST-SeqS
Cancer Research
medicine.medical_specialty
Treatment response
circulating tumor cells (CTCs)
lcsh:RC254-282
Article
03 medical and health sciences
0302 clinical medicine
Circulating tumor cell
Carcinoembryonic antigen
Internal medicine
medicine
Overall survival
biology
business.industry
treatment response
cell free circulating tumor DNA (ctDNA)
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
metastatic breast cancer (MBC)
prognosis
Predictive value
Metastatic breast cancer
3. Good health
Cancer antigen
030104 developmental biology
030220 oncology & carcinogenesis
Cohort
biology.protein
business
Subjects
Details
- Language :
- English
- ISSN :
- 20726694
- Volume :
- 11
- Issue :
- 8
- Database :
- OpenAIRE
- Journal :
- Cancers
- Accession number :
- edsair.doi.dedup.....030ebed85d2a3b757f9a264c459d302f